The chiral ligand creates an uneven catalytic environment around the metal center, making one pathway for hydrogen delivery more favorable than its mirror-image alternative. This preference determines which enantiomer forms predominantly. Ligand-controlled selectivity is therefore central to obtaining products with high enantiomeric purity rather than an approximately equal mixture of enantiomers.
The metal catalyst coordinates with both molecular hydrogen and the prochiral unsaturated substrate. Within the chiral catalytic environment, the substrate is oriented so that hydrogen delivery to one face of its carbon–carbon or carbon–heteroatom double bond is favored. That facial preference establishes the product’s dominant stereochemical outcome.
Controlled reaction conditions help preserve the balance between catalytic efficiency and stereoselectivity. If the process does not maintain conditions that support the desired catalytic pathway, formation of the preferred enantiomer may become less effective. Careful control is consequently important when the target is both efficient conversion and high enantiomeric purity.
The method applies to prochiral unsaturated compounds containing carbon–carbon or carbon–heteroatom double bonds. Because these substrates present two possible faces for hydrogen addition, a chiral catalyst can favor one stereochemical pathway. This broad substrate scope connects the reaction to the preparation of diverse chiral molecules in synthetic chemistry.
A prochiral unsaturated compound is combined with a metal catalyst coordinated to a chiral ligand, and molecular hydrogen is supplied under controlled reaction conditions. The catalyst activates hydrogen and the substrate, then promotes selective delivery across the unsaturated bond. The resulting product is enriched in one enantiomer.
Pharmaceuticals and agrochemicals often require chiral molecules with a defined three-dimensional arrangement. This reaction provides a route to favor one enantiomer while constructing the molecular framework, which can simplify access to biologically active compounds. Its use also extends to fine chemicals, where stereochemical control is an important synthetic objective.
Asymmetric hydrogenation can support more sustainable routes by combining catalytic reactivity with direct use of molecular hydrogen and selective formation of a desired enantiomer. High stereoselectivity may reduce the need to manage unwanted stereochemical products. These features make the process relevant to developing efficient routes for biologically active and other fine chemicals.